Dicyclomine Hydrochloride

Dicyclomine hydrochloride tablets are indicated for the treatment of patients with functional bowel/irritable bowel syndrome. Dicyclomine hydrochloride tablets are an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome ( 1 )

12.1 Mechanism of Action Dicyclomine relieves smooth muscle spasm of the gastrointestinal tract. Animal studies indicate that this action is achieved via a dual mechanism: ; a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites with approximately 1/8 the milligram potency of atropine ( in vitro , guinea pig ileum); and ; a direct effect upon smooth muscle (musculotropic) as evidenced by dicyclomine’s antagonism of bradykinin- and histamine-induced spasms of the isolated guinea pig ileum. Atropine did not affect responses to these two agonists.

Clinical clearance of Dicyclomine Hydrochloride (Anticholinergic) relies on hepatic enzymatic processing and renal clearance proportional to creatinine clearance (dicyclomine hydrochloride) with a Biphasic clearance with 5–12 hr terminal t½ under Dicyclomine Hydrochloride maintenance half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Dicyclomine Hydrochloride (20 mg/2mL Injection, Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after dicyclomine hydrochloride administration.

FDA clinical labeling for Dicyclomine Hydrochloride restricts administration in dicyclomine hydrochloride is contraindicated in infants less than 6 months of age , nursing mothers , and in patients with:; unstable cardiovascular status in acute hemorrhage; obstructive uropathy across 20 mg/2mL Injection, Solution, 10 mg/1 Capsule, 20 mg/1 Tablet, 10 mg/5mL Solution, 10 mg/mL Injection, Solution, with self-reported patient tracking dominated by nausea (9.1% of reports), headache (8.5% of reports), dizziness (6.9% of reports).